ERBA Diagnostics, Inc. Appoints William Creech as Vice President Sales and Marketing

        Print
| Source: Erba Diagnostics Inc

MIAMI LAKES, Fla., June 20, 2014 (GLOBE NEWSWIRE) -- ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, has appointed William Creech as Vice President Sales and Marketing.

Mr. Creech has over 20 years of successful experience in the diagnostics industry. His last assignment was with Vermillion Inc., a diagnostics company, as Vice President Sales and Marketing, leading the commercialization of a novel test for ovarian cancer. Prior to that, Mr. Creech worked in various capacities of increasing responsibilities with Abbott Laboratories Diagnostics Division, Siemens Healthcare and Thermo Fisher Scientific, where he was VP Sales and Marketing, Capitol Vial subsidiary.

Mohan Gopalkrishnan, Chief Executive Officer of ERBA Diagnostics, said, "Mr. Creech is a key addition to our management team and will focus on building a strong sales and marketing organization to deliver our growth objectives. We expect that his rich experience and knowledge of the diagnostics industry will add to our strategic focus in product development and future acquisitions."

About ERBA Diagnostics, Inc.

ERBA Diagnostics, Inc. (www.erbadiagnostics.com), headquartered in Miami Lakes, Florida, is a fully integrated in vitro diagnostics company that develops, manufactures and distributes in the United States and internationally, proprietary diagnostic reagents, test kits and instrumentation, primarily for autoimmune and infectious diseases, clinical chemistry, hematology and diabetes through its six subsidiaries – Diamedix Corporation (U.S.), Delta Biologicals S.r.l. (Europe), ImmunoVision, Inc. (U.S.), Drew Scientific, Inc. (U.S.), JAS Diagnostics, Inc. (U.S.), and Erba Diagnostics Mexico S.A. (Latin America).

Safe Harbor Statement

Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect the business and prospects of ERBA Diagnostics, Inc., including, without limitation: the risks and uncertainties associated with ERBA Diagnostics' business strategies, including, without limitation, the risk Mr. Creech's appointment may not build a strong sales and marketing organization, achieve growth objectives or increase focus in product development and future acquisitions, or otherwise; the risk Mr. Creech's appointment may not have a positive impact on ERBA Diagnostics' business strategies and may not be successful in ERBA Diagnostics achieving improved sales or operating results; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. In addition to the risks and uncertainties set forth above, investors should consider the economic, competitive, governmental, technological and other risks and uncertainties discussed in ERBA Diagnostics' filings with the Securities and Exchange Commission, including, without limitation, the risks and uncertainties discussed under the heading "Risk Factors" in such filings.

Company Contact:
Mohan Gopalkrishnan
Chief Executive Officer
Tel: 305 418 2320 x 319